235 related articles for article (PubMed ID: 26534869)
1. Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline.
Huffman DM; Farias Quipildor G; Mao K; Zhang X; Wan J; Apontes P; Cohen P; Barzilai N
Aging Cell; 2016 Feb; 15(1):181-6. PubMed ID: 26534869
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-I action on glucose transport in acute renal failure.
Mak RH; Mehls O
Am J Physiol; 1996 Aug; 271(2 Pt 2):F440-5. PubMed ID: 8770177
[TBL] [Abstract][Full Text] [Related]
3. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity.
Arafat AM; Weickert MO; Frystyk J; Spranger J; Schöfl C; Möhlig M; Pfeiffer AF
J Clin Endocrinol Metab; 2009 Dec; 94(12):5093-101. PubMed ID: 19846739
[TBL] [Abstract][Full Text] [Related]
4. Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats.
García-Fernández M; Delgado G; Puche JE; González-Barón S; Castilla Cortázar I
Endocrinology; 2008 May; 149(5):2433-42. PubMed ID: 18187555
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance but IGF-I sensitivity in chronic renal failure.
Mak RH
Am J Physiol; 1996 Jul; 271(1 Pt 2):F114-9. PubMed ID: 8760251
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent onset of liver-specific IGF-I gene deficiency and its persistence in old age: implications for postnatal growth and insulin resistance in LID mice.
Tang Z; Yu R; Lu Y; Parlow AF; Liu JL
Am J Physiol Endocrinol Metab; 2005 Aug; 289(2):E288-95. PubMed ID: 15769793
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-I improves glucose utilization in tumor necrosis factor-treated rats under hyperinsulinemic-euglycemic conditions.
Ling PR; Sierra P; Qu Z; Bistrian BR
Metabolism; 1997 Sep; 46(9):1052-8. PubMed ID: 9284895
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-1 and insulin resistance in skeletal muscles of adult and old rats.
Dardevet D; Sornet C; Attaix D; Baracos VE; Grizard J
Endocrinology; 1994 Mar; 134(3):1475-84. PubMed ID: 8119189
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between growth hormone/insulin-like growth factor-1 resistance and insulin resistance in non catch-up growth rats born small for gestational age].
Huang TT; Du ML; Ma HM; Su Z; Gu YF
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2292-6. PubMed ID: 18001556
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.
Benbassat CA; Maki KC; Unterman TG
J Clin Endocrinol Metab; 1997 May; 82(5):1484-91. PubMed ID: 9141538
[TBL] [Abstract][Full Text] [Related]
11. Normalisation of insulin-like growth factor-I does not improve insulin action in cirrhosis.
Nielsen MF; Aagaard NK; Grøfte T; Frystyk J; Greisen J; Christiansen JS; Holland-Fischer P; Vilstrup H
Liver Int; 2011 Nov; 31(10):1511-8. PubMed ID: 21967317
[TBL] [Abstract][Full Text] [Related]
12. Central IGF-1 protects against features of cognitive and sensorimotor decline with aging in male mice.
Farias Quipildor GE; Mao K; Hu Z; Novaj A; Cui MH; Gulinello M; Branch CA; Gubbi S; Patel K; Moellering DR; Tarantini S; Kiss T; Yabluchanskiy A; Ungvari Z; Sonntag WE; Huffman DM
Geroscience; 2019 Apr; 41(2):185-208. PubMed ID: 31076997
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
Cusi K; DeFronzo R
J Clin Endocrinol Metab; 2000 Sep; 85(9):3077-84. PubMed ID: 10999789
[TBL] [Abstract][Full Text] [Related]
15. Glucose disposal by insulin, but not IGF-1, is dependent on the hepatic parasympathetic nerves.
Sadri P; Lautt WW
Can J Physiol Pharmacol; 2000 Oct; 78(10):807-12. PubMed ID: 11077981
[TBL] [Abstract][Full Text] [Related]
16. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.
Pratipanawatr T; Pratipanawatr W; Rosen C; Berria R; Bajaj M; Cusi K; Mandarino L; Kashyap S; Belfort R; DeFronzo RA
Am J Physiol Endocrinol Metab; 2002 Jun; 282(6):E1360-8. PubMed ID: 12006367
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function.
Paolisso G; Ammendola S; Del Buono A; Gambardella A; Riondino M; Tagliamonte MR; Rizzo MR; Carella C; Varricchio M
J Clin Endocrinol Metab; 1997 Jul; 82(7):2204-9. PubMed ID: 9215295
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans.
Laager R; Ninnis R; Keller U
J Clin Invest; 1993 Oct; 92(4):1903-9. PubMed ID: 8408642
[TBL] [Abstract][Full Text] [Related]
19. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action.
Muzumdar RH; Ma X; Fishman S; Yang X; Atzmon G; Vuguin P; Einstein FH; Hwang D; Cohen P; Barzilai N
Diabetes; 2006 Oct; 55(10):2788-96. PubMed ID: 17003344
[TBL] [Abstract][Full Text] [Related]
20. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
